3 Key Takeaways From Canopy Growth’s (TSX:WEED) Q4 Results

Despite showing impressive sales growth in its most recent quarter, Canopy Growth Corp (TSX:WEED)(NYSE:CGC) continues to struggle with keeping its costs under control.

| More on:

Canopy Growth Corp (TSX:WEED)(NYSE:CGC) stock has been struggling in recent months amid a disappointing performance in Q4 that’s only made things worse. While sales continued to grow, so too did the company’s losses, calling into question the likelihood of Canopy Growth becoming EBITDA positive anytime soon.

Here are the three things that stood out to me from the company’s most recent quarterly results:

Operating expenses rose 332% while sales grew by 312% 

This is a troubling trend for Canopy Growth, as it suggests a lack of efficiency in the company’s operations — one that is seeing its expenses climb at a higher rate than its revenues. Canopy Growth saw big increases across all its major expense categories, including share-based compensation that increased by more than $60 million, a near $50 million rise in general and administration expenses, and sales and marketing expenses that were up by $38 million.

The challenge is that with edibles becoming legal later this year, they’ll be even more pressure on expenses, and those line items are likely to rise even more.

I’m a bit skeptical as to whether Canopy Growth can actually make any improvements here, yet changes will be needed in order for the company to have any real hope of reaching anywhere near breakeven.

In Q4, the company’s loss from operations totalled $174 million, which was more than triple the $51 million loss recorded last year.

Fair value gains of $53.5 million not enough to pull the company into the black

Canopy Growth received a big boost to its gross margin this quarter, as changes in fair value shot its gross profit up to $68 million, which was significantly higher than the $5 million recorded last year. In the prior year, the company incurred a loss of $2.5 million related to changes in fair value.

These fair value changes can create a lot of noise on the company’s financials, making it difficult to predict how it will do. What’s concerning is that even with a big benefit this quarter, it was still not nearly enough to pull Canopy Growth out of the red.

Gross margins of 15.9% were much lower than 33.6% last year

If Canopy Growth has any hope of being able to reach breakeven, its gross profits (before changes in fair value) will need to be a lot stronger. In Q4, this line item increased by just $7 million despite net sales increasing by more than $71 million.

It’s a discouraging sign that could be a problem, especially as more supply hits the markets, putting even more downward pressure on prices. These margins could get squeezed even further, rendering it more difficult to ensure that there’s enough left over to cover the company’s rising expenses.

Bottom line

There are some big concerns that investors should be aware of judging from Canopy Growth’s most recent quarterly results. As well, a great deal of change will be needed in order for the company to have much of a chance of reaching breakeven. As it stands today, unless the company has something significant planned, reaching breakeven doesn’t appear to be attainable anytime soon.

Fool contributor David Jagielski has no position in any of the stocks mentioned.

More on Cannabis Stocks

four people hold happy emoji masks
Dividend Stocks

Wary of Mining Companies? A Lower-Risk Way to Get in on the Gold and Silver Surge

Frenco-Nevada (TSX:FNV) stock might be a wiser way to play the run in gold prices this year.

Read more »

Cannabis smoke
Cannabis Stocks

Have Cannabis Stocks Totally Gone Up in Smoke?

Let's dive into whether Canadian cannabis stocks are still investable, and what investors should make of the recent volatility in…

Read more »

Researcher works in hemp field
Cannabis Stocks

1 Undervalued Cannabis Stock to Buy and Hold Over the Next Decade

Green Thumb is a beaten-down cannabis stock that trades at a compelling valuation in September 2025.

Read more »

Researcher works in hemp field
Cannabis Stocks

Pot Stocks Rallied Hard in August: Is There More to Come?

Tilray Brands (TSX:TLRY) and the broad basket of pot stocks could heat up from here.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Canopy Growth Stock Jumped 30% Last Month: What’s Going on?

Canopy Growth (TSX:WEED) stock is picking up traction again, making it an enticing weed play to buy on strength.

Read more »

A cannabis plant grows.
Cannabis Stocks

These Threats Facing Canopy Growth Stock Could Justify Selling it

Let's dive into whether Canopy Growth (TSX:WEED) is a top stock investors should buy right now after its recent dip…

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

This BioCannabis Firm Could Explode with Product Approval

This cannabis stock used to be a major name, so where does it stand now?

Read more »

Medicinal research is conducted on cannabis.
Stocks for Beginners

This TSX Health-Care Stock Is a Long-Term Buy for Patient Investors

This TSX stock continues to be one of the best long-term opportunities, if you're patient.

Read more »